TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06036004
Drug: Intranasal OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment.
Study: NCT06434363
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein (IV)
Study: NCT06592924
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice. Assigned prior to enrollment
Study: NCT06188026
Drug: ethinylestradiol/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
Study: NCT05308940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Study: NCT05308940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study: NCT05364021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for LP352 administered three times daily, orally or through G-tube
Study: NCT06575933
Drug: MK-1084
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06760819
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT06344104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally, once daily (QD).
Study: NCT05563844
Drug: PM 8.4 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
Study: NCT05563844
Drug: PM 11.2 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
Study: NCT05463094
Drug: Test Glucophage® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
Study: NCT05463094
Drug: Reference Glucophage® XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
Study: NCT05753189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Proprietary Vehicle Solution
Study: NCT06786767
Drug: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.
Study: NCT06652113
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
Study: NCT06261450
Drug: CBD Oral Solution (eCBD system Target)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
Study: NCT06261450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
Study: NCT06346197
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Study: NCT06346197
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Study: NCT06700811
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ketogenic diet formula will be supplied by KetoVie®. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 0.3mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1 (goal 4:1, minimum 1:1 if required for tolerance or high BHB) and will not exceed this ratio. Higher ratios are often required to obtain ketosis of ideally 2-5mmol/L in infants.
Study: NCT06704113
Drug: meloxicam 7,5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
Study: NCT05788237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline for injection
Study: NCT06269146
Drug: Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match the study drug in mode of administration, color, size, and taste.
Study: NCT05488847
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preoperative pain medication given to all patients
Study: NCT05488847
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative and discharge pain medication given to all patients
Study: NCT05488847
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative pain medication given to all patients
Study: NCT05488847
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative pain medication given to all patients
Study: NCT05488847
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative pain medication given to all patients
Study: NCT05488847
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discharge pain medication given to all patients
Study: NCT05764161
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
Study: NCT06497660
Drug: Deoxyadrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxyadrenaline is a vasoactive drug
Study: NCT06497660
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxyadrenaline is a vasoactive drug
Study: NCT05412394
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid, 5mg/kg per week, for one year
Study: NCT06232902
Drug: QL1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
Study: NCT06480565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for Lymphodepletion
Study: NCT06486441
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05076591
Drug: IMM2902
Approvals — FDA: no, EMA: no, PMDA: no
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Study: NCT04852328
Drug: CUE-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
Study: NCT06311760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as IV infusion.
Study: NCT04931147
Drug: RXC007
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses.
Study: NCT06213818
Drug: INCB160058
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Immediate release solid tablet
Study: NCT06213818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT06213818
Drug: INCB160058
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Soft gel capsule
Study: NCT06213818
Drug: INCB160058
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Amorphous solid dispersion (ASD) Tablet
Study: NCT04931147
Drug: RXC007 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study.
Study: NCT06268145
Drug: ECC5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
Study: NCT06322407
Drug: standardized drug treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
Study: NCT05216328
Drug: Macrogol Only Product in Oral Dose Form
Normalized name: Macrogol only product in oral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information already included in arm/group description.
Study: NCT05469854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral tablets
Study: NCT05559580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05153330
Drug: BMF-219
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
Study: NCT06736574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06788080
Drug: BioRBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous biotin-labeled RBCs will be transfused to study participants
Study: NCT06782646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
Study: NCT06485401
Drug: ADC189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg per tablet, oral administration, single dose.
Study: NCT06342947
Drug: ALG-055009
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel Capsule
Study: NCT06342947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel Capsule
Study: NCT05330143
Drug: ASC22 1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
Study: NCT05330143
Drug: ASC22 2.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
Study: NCT04650087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Study: NCT05330143
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard antiretroviral therapy including Integrase inhibitors (INSTIs)
Study: NCT05330143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline vials administered subcutaneously once 4 week.
Study: NCT06170840
Drug: QY101Placebo/QY101 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: External use for BID
Study: NCT06485245
Drug: CS060304
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06708299
Drug: CardiolRx
Normalized name: CARDIOTEX RX TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will be administered orally (via syringe) with food twice daily.
Study: NCT06564493
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT06106828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection
Study: NCT06333769
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.
Study: NCT05047783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05847517
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted.
Study: NCT06478719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT04678323
Drug: Lifestyle Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive lifestyle management.
Study: NCT06692166
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Study: NCT06692166
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
Study: NCT05445479
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient with doxycycline treatment during COVID-19 waves
Study: NCT04509102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
Study: NCT06430385
Drug: ION440
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION440 will be administered by intrathecal bolus (ITB) injection.
Study: NCT04855747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05911841
Drug: LY3454738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05911841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06540326
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
Study: NCT05853120
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
Study: NCT06279234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06279234
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT06257277
Drug: GBCAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBCAs are given per routine clinical practice.
Study: NCT06351501
Drug: hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
Study: NCT06351501
Drug: Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of hormonal treatment from 16 old +/- 6 months to 18 years old +/- 6 months
Study: NCT06408298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablet
Study: NCT05682352
Drug: LEO 158968
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion or SC injection
Study: NCT05682352
Drug: LEO 158968
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC injection
Study: NCT05682352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05683184
Drug: [11C]OMAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
Study: NCT04566991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
Study: NCT06012708
Drug: KN510 60mg/day + KN713 60mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Study: NCT06012708
Drug: KN510 120mg/day + KN713 60mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Study: NCT06012708
Drug: KN510 120mg/day + KN713 90mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Study: NCT06012708
Drug: KN510 120mg/day + KN713 120mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily with 28 days (4 weeks) as one cycle.
Study: NCT06033846
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
Study: NCT04486157
Drug: IN-A012
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
Study: NCT04486157
Drug: Akynzeo 300Mg-0.5Mg Capsule
Normalized name: Akynzeo 300mg-0.5mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be administrated Akynzeo by Orally with water.
Study: NCT04266275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.
Study: NCT05773820
Drug: WJB001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.